Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It is also developing ATA188 and autologous ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product to treat Wilms tumor 1; and ATA230, which is Phase II clinical trials for refractory cytomegalovirus. In addition, the company is developing ATA368 that is under preclinical development for HIV and cancers. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with Moffitt Cancer Center. The company was founded in 2012 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATRA
Previous Symbol
CUSIPN/A
Phone650-278-8930
Debt
Debt-to-Equity RatioN/A
Current Ratio13.81
Quick Ratio13.81
Price-To-Earnings
Trailing P/E Ratio-10.43
Forward P/E Ratio-8.66
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.73 per share
Price / Book8.82
Profitability
EPS (Most Recent Fiscal Year)($4.00)
Net Income$-119,490,000.00
Net MarginsN/A
Return on Equity-50.63%
Return on Assets-45.83%
Miscellaneous
Employees185
Outstanding Shares45,650,000
Market Cap$1.94 billion
OptionableOptionable
Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions
What is Atara Biotherapeutics' stock symbol?
Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."
How were Atara Biotherapeutics' earnings last quarter?
Atara Biotherapeutics Inc (NASDAQ:ATRA) released its quarterly earnings results on Tuesday, November, 6th. The biotechnology company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.13) by $0.16. View Atara Biotherapeutics' Earnings History.
When is Atara Biotherapeutics' next earnings date?
What price target have analysts set for ATRA?
8 brokerages have issued twelve-month target prices for Atara Biotherapeutics' shares. Their predictions range from $23.00 to $70.00. On average, they anticipate Atara Biotherapeutics' stock price to reach $48.50 in the next twelve months. This suggests a possible upside of 16.3% from the stock's current price. View Analyst Price Targets for Atara Biotherapeutics.
What is the consensus analysts' recommendation for Atara Biotherapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atara Biotherapeutics.
Has Atara Biotherapeutics been receiving favorable news coverage?
News headlines about ATRA stock have trended somewhat negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Atara Biotherapeutics earned a news impact score of -1.1 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the company's share price in the immediate future.
Who are some of Atara Biotherapeutics' key competitors?
Some companies that are related to Atara Biotherapeutics include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX) and Rubius Therapeutics (RUBY).
Who are Atara Biotherapeutics' key executives?
Atara Biotherapeutics' management team includes the folowing people:
- Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 47)
- Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 48)
- Dr. Derrell D. Porter, Sr. VP & Global Commercial Head (Age 47)
- Mr. Utpal Koppikar, Chief Financial Officer
- Dr. Christopher M. Haqq, Exec. VP of R&D & Chief Scientific Officer (Age 52)
Who are Atara Biotherapeutics' major shareholders?
Atara Biotherapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (11.43%), Redmile Group LLC (9.24%), BlackRock Inc. (7.70%), Vanguard Group Inc. (5.45%), Vanguard Group Inc (5.45%) and Morgan Stanley (4.14%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Gad Soffer, Heather D Turner, Isaac E Ciechanover, Joe Newell, John Mcgrath, Matthew K Fust, Mitchall G Clark and Utpal Koppikar. View Institutional Ownership Trends for Atara Biotherapeutics.
Which institutional investors are selling Atara Biotherapeutics stock?
ATRA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Wells Fargo & Company MN, University of Notre Dame DU Lac, Morgan Stanley, Putnam Investments LLC, Credit Suisse AG, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp and TIAA CREF Investment Management LLC. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Heather D Turner, Isaac E Ciechanover, Joe Newell, John Mcgrath, Matthew K Fust and Mitchall G Clark. View Insider Buying and Selling for Atara Biotherapeutics.
Which institutional investors are buying Atara Biotherapeutics stock?
ATRA stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Dimensional Fund Advisors LP, Assenagon Asset Management S.A., Eagle Asset Management Inc., BlackRock Inc., Vanguard Group Inc and Vanguard Group Inc.. View Insider Buying and Selling for Atara Biotherapeutics.
How do I buy shares of Atara Biotherapeutics?
Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Atara Biotherapeutics' stock price today?
One share of ATRA stock can currently be purchased for approximately $41.72.
How big of a company is Atara Biotherapeutics?
Atara Biotherapeutics has a market capitalization of $1.94 billion. The biotechnology company earns $-119,490,000.00 in net income (profit) each year or ($4.00) on an earnings per share basis. Atara Biotherapeutics employs 185 workers across the globe.
What is Atara Biotherapeutics' official website?
How can I contact Atara Biotherapeutics?
Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.
MarketBeat Community Rating for Atara Biotherapeutics (NASDAQ ATRA)
MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe ATRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
